Silexion Therapeutics stock falls after warrant exercise deal

Published 01/08/2025, 13:48
© Reuters.

Investing.com -- Silexion Therapeutics Corp (NASDAQ:SLXN) stock tumbled 22.4% in pre-market trading after the clinical-stage biotech company announced definitive agreements for the immediate exercise of certain outstanding warrants.

The agreements involve the exercise of warrants to purchase up to 152,106 of the company’s ordinary shares at a reduced exercise price of $11.57 per share, down from their original price when issued in January 2025. The transaction is expected to generate approximately $1.8 million in gross proceeds for Silexion, which develops RNA interference therapies for KRAS-driven cancers.

As part of the deal, Silexion will issue new unregistered warrants to purchase up to 304,212 of the company’s ordinary shares. These new warrants will have an exercise price of $11.32 per share and a term of twenty-four months, but can only be exercised following shareholder approval to increase the company’s authorized ordinary shares.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering, which is expected to close around August 1, 2025. Silexion intends to use the proceeds as working capital for general corporate purposes.

The ordinary shares issuable upon exercise of the original warrants are already registered under effective registration statements on Form S-1.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.